GlaxoSmithKline Muscular Dystrophy Drug Achieves Primary Objective Study

Bloomberg reported that GlaxoSmithKline Plc’s competition with Sarepta Therapeutics Inc has heated up as its Duchenne muscular dystrophy drug, known as Drisapersen, achieved primary objective study.

As quoted in the market news:

Duchenne muscular dystrophy is a neuromuscular disease with no known cure that affects one in 3,500 newborn boys. Drisapersen has been designated by U.S. and European regulators as an orphan drug, and may eventually reach 500 million pounds ($766 million) in sales if proven to be effective and approved for commercialization, according to Fabian Wenner, an analyst at Kepler Capital Markets in Zurich.

Click here to read the full Bloomberg report.